Effexor
What is Effexor (Venlafaxine)?
Approved To Treat
Top Global Experts
Related Clinical Trials
Summary: Over half of women in the US who are breastfeeding their infants take prescription drugs. You are being asked to participate in this study because you are breastfeeding your infant and are currently taking, as part of your medical care, at least one of the drugs we are studying. We are interested in studying drugs commonly prescribed to women who are breastfeeding so we can learn more about the am...
Summary: Fibromyalgia is a chronic pain syndrome where current medications have limited efficacy and a slow onset of action. Esketamine shows potential as a rapid-acting analgesic, but previous low-dose studies failed to demonstrate long-term benefits. The efficacy of higher-dose ESK as an adjunctive therapy when standard treatments are insufficient remains unclear.
Summary: Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Recent attention has focused on the ...
Related Latest Advances
Brand Information
- Major Depressive Disorder (MDD)
- Generalized Anxiety Disorder (GAD)
- Social Anxiety Disorder (SAD)
- Panic Disorder (PD)
- 37.5 mg extended-release capsule: grey cap and peach body with "W" and "Effexor XR" on the cap and "37.5" on the body
- 75 mg extended-release capsule: peach cap and body with "W" and "Effexor XR" on the cap and "75" on the body
- 150 mg extended-release capsule: dark orange cap and body with "W" and "Effexor XR" on the cap and "150" on the body
- with known hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate or to any excipients in the formulation
- taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of the risk of serotonin syndrome
- Hypersensitivity
- Suicidal Thoughts and Behaviors in Adolescents and Young Adults
- Serotonin Syndrome
- Elevated Blood Pressure
- Increased Risk of Bleeding
- Angle-Closure Glaucoma
- Activation of Mania/Hypomania
- Discontinuation Syndrome
- Seizure
- Hyponatremia
- Weight and Height changes in Pediatric Patients
- Appetite Changes in Pediatric Patients
- Interstitial Lung Disease and Eosinophilic Pneumonia
- Sexual Dysfunction

- 37.5 mg, grey cap/peach body with "W" and "Effexor XR" on the cap and "37.5" on the body.
- 75 mg, peach cap and body with "W" and "Effexor XR" on the cap and "75" on the body.
- 150 mg, dark orange cap and body with "W" and "Effexor XR" on the cap and "150" on the body.

(venlafaxine HCl)
Extended-Release Capsules
37.5 mg

NDC 0008-0837-03
(venlafaxine HCl)
Extended-Release Capsules


(venlafaxine HCl)
Extended-Release Capsules
75 mg

NDC 0008-0833-03
(venlafaxine HCl)
Extended-Release Capsules


(venlafaxine HCl)
Extended-Release Capsules
150 mg

NDC 0008-0836-03
(venlafaxine HCl)
Extended-Release Capsules



